Phase II evaluation of suramin in advanced renal cell carcinoma. A Southwest Oncology Group study.
Twenty-two eligible patients with advanced renal carcinoma were treated with suramin utilizing a fixed dose regimen. Therapy was reasonably well tolerated with 3 of 22 patients (14%) developing grade 4 toxicity and 11 of 22 patients (50%) having a maximum toxicity of grade 3. There were no responders; median survival was 10 months. Suramin is not an active agent in advanced renal carcinoma.
Schroder
L E.
LE
University of Cincinnati Medical Center, Barrett Cancer Center, P.O. Box 670501, 45219-0501, USA, Cincinnati, OH, USA
Lew
D
D
Flanigan
R C.
RC
Eisenberger
M A.
MA
Seay
T E.
TE
Hammond
N
N
Needles
B M.
BM
Crawford
E D.
ED